Takeda’s TAK-279 meets primary endpoint in Phase 2b trial for psoriatic arthritis

Takeda Pharmaceutical Company announced positive results from its Phase 2b clinical trial for TAK-279, an investigational oral TYK2 inhibitor for treating psoriatic arthritis. Meeting its ... Read More